Literature DB >> 21384315

Standardized extracts from hawthorn leaves and flowers in the treatment of cardiovascular disorders--preclinical and clinical studies.

Egon Koch1, Fathi Abdul Malek.   

Abstract

Extracts from different parts of hawthorn plants (Crataegus spp.) are used worldwide for the treatment of cardiovascular diseases. So far, almost all clinical studies have been conducted with standardized hydroalcoholic extracts from leaves and flowers. These trials with more than 4000 patients have provided evidence for clinical benefits in the therapy of mild chronic heart failure. Besides cardiotonic effects, recent pharmacological investigations indicate that hawthorn extracts also possess cardio- and vasoprotective properties. Thus, these extracts may also be employed in the prophylactic and therapeutic treatment of such conditions as endothelial dysfunction, atherosclerosis, coronary heart disease, or prevention of restenosis/reocclusion following peripheral endovascular treatment. In this review the pharmacological and clinical data relating to these standardized extracts are summarized. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21384315     DOI: 10.1055/s-0030-1270849

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  10 in total

1.  Endothelial Glycocalyx-Mediated Nitric Oxide Production in Response to Selective AFM Pulling.

Authors:  Anne Marie W Bartosch; Rick Mathews; John M Tarbell
Journal:  Biophys J       Date:  2017-07-11       Impact factor: 4.033

2.  Use of antifungal saponin SC-2 of Solanum chrysotrichum for the treatment of vulvovaginal candidiasis: in vitro studies and clinical experiences.

Authors:  Armando Herrera-Arellano; Edgar O López-Villegas; Aida V Rodríguez-Tovar; Alejandro Zamilpa; Enrique Jiménez-Ferrer; Jaime Tortoriello; M Angeles Martínez-Rivera
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-04-12

3.  Nanomechanics and sodium permeability of endothelial surface layer modulated by hawthorn extract WS 1442.

Authors:  Wladimir Peters; Verena Drüppel; Verena Drueppel; Kristina Kusche-Vihrog; Carola Schubert; Hans Oberleithner
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

Review 4.  Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach.

Authors:  Jie Wang; Xingjiang Xiong; Bo Feng
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-29       Impact factor: 2.629

Review 5.  Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review.

Authors:  Christian J F Holubarsch; Wilson S Colucci; Jaan Eha
Journal:  Am J Cardiovasc Drugs       Date:  2018-02       Impact factor: 3.571

6.  Crataegus Extract WS®1442 Stimulates Cardiomyogenesis and Angiogenesis From Stem Cells: A Possible New Pharmacology for Hawthorn?

Authors:  Jonas Halver; Kristin Wenzel; Jandirk Sendker; Carmen Carrillo García; Clemens A J Erdelmeier; Erik Willems; Mark Mercola; Nico Symma; Stephanie Könemann; Egon Koch; Andreas Hensel; Dennis Schade
Journal:  Front Pharmacol       Date:  2019-11-27       Impact factor: 5.810

7.  Optimizing Water-Based Extraction of Bioactive Principles of Hawthorn: From Experimental Laboratory Research to Homemade Preparations.

Authors:  Phu Cao Ngoc; Laurent Leclercq; Jean-Christophe Rossi; Isabelle Desvignes; Jasmine Hertzog; Anne-Sylvie Fabiano-Tixier; Farid Chemat; Philippe Schmitt-Kopplin; Hervé Cottet
Journal:  Molecules       Date:  2019-12-03       Impact factor: 4.411

8.  Procyanidin C1 from Viola odorata L. inhibits Na+,K+-ATPase.

Authors:  Tomas Heger; Marek Zatloukal; Martin Kubala; Miroslav Strnad; Jiri Gruz
Journal:  Sci Rep       Date:  2022-04-29       Impact factor: 4.996

9.  Exploring the Mechanism of Hawthorn Leaves Against Coronary Heart Disease Using Network Pharmacology and Molecular Docking.

Authors:  Jie Ding; Jun Wu; Haoran Wei; Sui Li; Man Huang; Yan Wang; Qin Fang
Journal:  Front Cardiovasc Med       Date:  2022-06-16

10.  Complementary and alternative medicine and cardiovascular disease: an evidence-based review.

Authors:  Matthew J Rabito; Alan David Kaye
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-22       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.